



Vision

Improving the health of Minnesotans by advancing regenerative medicine therapies.

Goals

- Advance regenerative medicine research, education, industries, and care delivery to patients.
- Establish Minnesota at the forefront of regenerative medicine science and practice.

Objectives

- Scientific:** Support Minnesota research that has the potential to translate into clinical advances in regenerative medicine.
- Commercial:** Develop Minnesota businesses and infrastructure to deliver regenerative medicine products and services.
- Educational:** Educate, recruit and retain a regenerative medicine workforce in Minnesota. Educate Minnesotans on regenerative medicine therapies.
- Clinical:** Bring regenerative medicine therapies across the State, including underserved populations.

Governance

Recommendations governing the Regenerative Medicine Minnesota (RMM) funding will be made by a five-person Board. The Regenerative Medicine Minnesota Board (Board) will have representatives from the University of Minnesota and Mayo Clinic as co-chairs, with three additional Minnesotans from fields as diverse as patient advocacy, industry, and health care. Members will also preferably have expertise pertinent to regenerative medicine, medical or basic science research, clinical translation, patient advocacy, education, and/or biobusiness/biotechnology development.

The Board is responsible for approving a business plan that outlines the RMM's vision, goals, objectives, funding priorities, and marketing and communications efforts. The board is also responsible for overseeing the review of applications and providing recommendations for distribution of funds. The Board has the authority to recommend reallocating funding among RMM funding categories based on need or on the quality of applications received. The Board is responsible for overseeing the progress of funded projects. An audit is submitted to the Minnesota State Legislature every other year in line

with the appropriation bill. Results are made public and available to Minnesotans via the dedicated website.

The oversight of RMM lies with senior officials of the University of Minnesota (Vice President for Research and Vice Dean for Research, Medical School) and Mayo Clinic (Executive Dean for Research and the Director of the Center for Clinical and Translational Science). To ensure that RMM meets the legislative intent of a broad statewide program and that the program meets all requisite legal and financial requirements, these four officials will act together to provide final oversight of the business plan and RMM board recommendations regarding funding and other strategic issues. RMM is independent of other University-Mayo collaborations.

Definition of Regenerative Medicine

Regenerative medicine utilizes the body's own ability to heal. Restoring form and function is at the essence of a regenerative outcome. Cell and developmental biology, regenerative pharmacology and immunology, medicine and surgery, biotechnology, bioengineering, and other relevant fields are brought together to develop ways to replace, restore, or regenerate damaged or malfunctioning cells, tissues, and organs to help people return to better health.

Funding Opportunity Guidelines

Regenerative Medicine Minnesota **will engage a network of stakeholders to develop regenerative medicine assets throughout the state.** Funding opportunities will emphasize statewide access and be balanced across development needs in research, clinical practice, business development, and education. Eligible institutions include public and private schools, colleges and universities, hospitals and clinics, health departments, research organizations, and biotechnology or other companies/organizations that are based in the state of Minnesota. Funds must primarily remain in Minnesota. Awardees are strongly encouraged to seek matching funds or in-kind contributions. Funds that remain unspent are returned to RMM, and the RMM Board will decide how to repurpose them.

Proposed Annual Budget

Discovery Science, Translational Research, and Clinical Trials	\$3,000,000
Education & Outreach	\$650,000
Biobusiness Development	\$500,000
Patient Care	\$200,000
Total	\$4,350,000
State Appropriation	\$4,350,000

Note: any unspent fund from any category becomes available for reallocation across other categories

FUNDING CATEGORIES

RESEARCH:

RFPs released 9/23/2019, proposals due 11/4/2019, awards announced 1/20/2020

- One- or two-year projects (2nd year renewal contingent on adequate progress) with the potential to advance regenerative medicine. Awarded based on independent scientific peer review.
 - Discovery science maximum award \$125,000/year.*
 - Translational research maximum award \$125,000/year.*
 - Clinical trials maximum award \$250,000/year.*

**Award amount includes indirect costs. Indirect costs should be included in the budget at the established NIH-negotiated rate or, in the absence of a federally negotiated rate, at 10%.*

BIOBUSINESS DEVELOPMENT:

RFP released 1/27/2020, proposals due 2/24/2020, awards announced 4/6/2020

- Projects to develop Minnesota businesses and technologies that deliver regenerative medicine products, devices, and services. May include purchase of non-expendable research equipment, creation of jobs, and/or development of infrastructure to produce regenerative biotechnology products, devices and services.
 - Maximum award \$100,000/year.

EDUCATION:

RFP released 1/27/2020, proposals due 2/24/2020, awards announced 4/6/2020

- Programs that improve student knowledge in regenerative science and medicine in grades K-12 by including curriculum on biology, medicine, engineering, healthcare, and/or other fields related to regenerative medicine.
 - Maximum award \$20,000/year.
- Programs that recruit and/or retain outstanding college students in areas of regenerative science and/or provide regenerative medicine-specific education.
 - Undergraduate maximum award \$50,000/year.
 - Graduate (including PhD) maximum award \$75,000/year.

CLINICAL CARE:

RFP released 1/27/2020, proposals due 2/24/2020, awards announced 4/6/2020

- Projects that benefit multiple patients by creating or updating access to regenerative medicine throughout the state.
 - Maximum award \$50,000/year.

OUTREACH:

Annual report of progress due from vendor on 11/4/2019. If unsatisfactory, RFP will be released 1/27/2020, proposals due 2/24/2020, awards announced 4/6/2020.

- Website: maintenance of website to track existing and future Minnesota regenerative medicine assets, educate the community, promote funding opportunities, and publicize the funded projects and their outcomes.
 - Maximum budget \$50,000/year.